Mapping Array Library Sample Clauses

Mapping Array Library. After SB screens the Compass Array Library and thereafter at any point during additional screening activities (as described below) on Available Compounds from the Compass Array Library, and as determined by SB in consultation with the JSC, SB may screen one or more Mapping Array Libraries corresponding to any Active Compound(s) identified from the Compass Array Library to obtain initial structure-activity ***** Confidential Treatment has been requested for the marked portion.
Sample 1
AutoNDA by SimpleDocs
Mapping Array Library. During the period from the [*****] upon the written request of Sankyo, ArQule will promptly deliver to Sankyo any Mapping Array Libraries selected by Sankyo. Promptly upon its receipt of any such Mapping Array Libraries, Sankyo shall test such Mapping Array Libraries for activity against the relevant Targets. In addition, Sankyo may continue to screen all Mapping Array Libraries received prior to the Effective Date against any Targets. Initially, ArQule will identify the Chemical Themes of each Mapping Array Library in [*****] but not the structures of the individual ArQule Compounds in the Mapping Array Library, and Sankyo will not disclose the Targets screened. If Sankyo detects Active Compounds, Sankyo shall promptly provide ArQule with notice by telefax communication of the spatial location of Active Compounds in the Mapping Array Libraries, which telefax shall be followed by a confirmatory letter.
Sample 1
Mapping Array Library. Upon receipt of each Mapping Array Library, or upon receipt of the relevant information as described in Section 3.3. in the case of Mapping Array Libraries already in the possession of Solvay, Solvay shall diligently screen such Mapping Array Library for activity against the relevant Target(s). ArQule will maintain the reserved status of the Available Compound(s) identified in the Compass Array Library for a period of four (4) months after Solvay receives the relevant Mapping Array Library and accompanying information or, in the case of Mapping Array Libraries already in the possession of Solvay, for a period of four (4) months after Solvay receives the relevant information as described in Section 3.3. In addition, Solvay shall have the right to screen all Mapping Array Libraries in its possession irrespective of the Compass Array Library. If Solvay detects and confirms Active Compounds, Solvay shall inform ArQule through the Research Committee in writing (including by electronic mail) of the spatial location of Active Compounds in the Mapping Array Libraries. ArQule will promptly determine whether the Active Compounds identified by Solvay in the Mapping Array Libraries are Available Compounds, and then notify Solvay of such determination. If any Active Compound is not an Available Compound, ArQule shall not disclose the structure and Solvay shall have no rights under this Agreement with respect to that Active Compound. If an Active Compound is an Available Compound, ArQule shall reserve such Active Compound as an Available Compound to Solvay under this Agreement. ArQule then shall disclose to Solvay the structure of such Available Compound correlated to its well location, and Solvay shall disclose to ArQule the class of the Target involved. All such disclosed structures and the target class shall be treated as Confidential Information. ArQule shall maintain the reserved status of every Active Compound that is an Available Compound from the same Mapping Array Library for a period of up to four (4) weeks after the date upon which the last structure of these Available Compounds is disclosed to Solvay. If Solvay requests resynthesis of one or more Available Compounds from the same Mapping Array Library during the four-week reservation period, the Research Committee will determine which of these Available Compounds if not all would become a Licensed Compound Set if the resynthesized compounds are confirmed to be Active Compounds, and ArQule will continue to re...
Sample 1
Mapping Array Library. Upon receipt of each Mapping Array Library, or upon receipt of the relevant information as described in Section 3.3. in the case of Mapping Array Libraries already in the possession of Solvay, Solvay shall diligently screen such Mapping Array Library for activity against the relevant Target(s). ArQule will maintain the reserved status of the Available Compound(s) identified in the Compass Array Library for a period of
Sample 1
Mapping Array Library. During the period from the Effective Date through March 31, 2003 upon the written request of Sankyo, ArQule will promptly deliver to Sankyo any Mapping Array Libraries selected by Sankyo. Promptly upon its receipt of any such Mapping Array Libraries, Sankyo shall test such Mapping Array Libraries for activity against the relevant Targets. In addition, Sankyo may continue to screen all Mapping Array Libraries received prior to the Effective Date against any Targets. Initially, ArQule will identify the Chemical Themes of each Mapping Array Library in Markush format but not the structures of the individual ArQule Compounds in the Mapping Array Library, and Sankyo will not disclose the Targets screened. If Sankyo detects Active Compounds, Sankyo shall promptly provide ArQule with notice by telefax communication of the spatial location of Active Compounds in the Mapping Array Libraries, which telefax shall be followed by a confirmatory letter.
Sample 1

Related to Mapping Array Library

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than [***].

  • Field The term “

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).

  • Development Funding (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Site Visits DOE’s authorized representatives have the right to make site visits at reasonable times to review project accomplishments and management control systems and to provide technical assistance, if required. You must provide, and must require your subawardees to provide, reasonable access to facilities, office space, resources, and assistance for the safety and convenience of the government representatives in the performance of their duties. All site visits and evaluations must be performed in a manner that does not unduly interfere with or delay the work.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Site Visits and Inspections; Regulatory Examinations During the term of this Agreement, authorized representatives of the Fund may conduct periodic site visits of the Transfer Agent’s facilities and inspect the Transfer Agent’s records and procedures solely as they pertain to the Transfer Agent’s services for the Fund under or pursuant to this Agreement. Such inspections shall be conducted at the Fund’s expense (which shall include costs related to providing materials, copying, faxing, retrieving stored materials, and similar expenses) and shall occur during the Transfer Agent’s regular business hours and, except as otherwise agreed to by the parties, no more frequently than twice a year. In connection with such site visit and/or inspection, the Fund shall not attempt to access, nor will it review, the records of any other clients of the Transfer Agent and the Fund shall conduct the visit/inspection in a manner that will not interfere with the Transfer Agent’s normal and customary conduct of its business activities, including the provision of services to the Fund and to other clients. The Transfer Agent shall have the right to immediately require the removal of any Fund representatives from its premises in the event that their actions, in the reasonable opinion of the Transfer Agent, jeopardize the information security of its systems and/or other client data or otherwise are disruptive to the business of the Transfer Agent. The Transfer Agent may require any persons seeking access to its facilities to provide reasonable evidence of their authority. The Transfer Agent may also reasonably require any of the Fund’s representatives to execute a confidentiality agreement before granting such individuals access to its facilities. The Transfer Agent will also provide reasonable access to the Fund’s governmental regulators, at the Fund’s expense, solely to (i) the Fund’s records held by the Transfer Agent and (ii) the procedures of the Transfer Agent directly related to its provision of services to the Fund under the Agreement.

  • Supply of Materials Unless the parties otherwise agree in a Work Order, Manufacturer will supply, in accordance with the relevant approved raw material specifications, all materials to be used by Manufacturer in the performance of Services under a Work Order other than the Rhythm Materials specified in such Work Order. Rhythm or its designees will provide Manufacturer with the Rhythm Materials. Manufacturer agrees (a) to account for all Rhythm Materials, (b) not to provide Rhythm Materials to any third party (other than an Affiliate acting as a permitted subcontractor) without the express prior written consent of Rhythm, (c) not to use Rhythm Materials for any purpose other than conducting the Services, including, without limitation, not to analyze, characterize, modify or reverse engineer any Rhythm Materials or take any action to determine the structure or composition of any Rhythm Materials unless required * CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. pursuant to a signed Work Order, and (d) to destroy or return to Rhythm all unused quantities of Rhythm Materials according to Rhythm’s written directions.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.